Showing 6471-6480 of 8473 results for "".
- Cloudy with a Chance of Wrinkles: ROC Ranks US Cities By Wrinkle Indexhttps://practicaldermatology.com/news/cloudy-with-a-chance-of-wrinkles-roc-ranks-cities-by-wrinkle-index/2458453/Philadelphia will be the most wrinkle-prone city in America come 2040 thanks to high stress levels, more airborne pollution, lengthy commute times and higher than average smoking rates, according to the 2016 RoC® Wrinkle Ranking. San Jose, Calif. will hold the least wrinkle-pron
- Chris Payne Named Chief Marketing Officer at PCA Skinhttps://practicaldermatology.com/news/chris-payne-named-chief-marketing-officer-at-pca-skin/2458454/Chris Payne has been named Chief Marketing Officer at Scottsdale, AZ-based PCA Skin. In this role, Payne will be responsible for leading all marketing and communication initiatives to drive growth of PCA SKIN through both professional and consum
- Oculus Innovative Sciences Receives FDA Approval for Post-Dermal-Procedures Producthttps://practicaldermatology.com/news/oculus-innovative-sciences-receives-fda-approval-for-post-dermal-procedures-product/2458455/The FDA awarded Oculus Innovative Sciences, Inc. 510(k) clearance for its new post-dermal-procedures product. Under the supervision of a healthcare professional, the product is intended for the removal of foreign material including microogranisms and debris from postdermal procedures. <
- 23andMe Data Helps ID BCC Risk Geneshttps://practicaldermatology.com/news/23andme-data-helps-id-bcc-risk-genes/2458459/New research out of 23andMe and Stanford University School of Medicine pinpoints 31 genetic associations for basal cell carcinoma (BCC), 14 of which are all new. Taken together, these associations are estimated to explain almost 11 percent of the genetic risk for BCC, according to t
- Billionaire John Paul DeJoria Bets Big on Aubío for Cold Sores and Maybe Morehttps://practicaldermatology.com/news/billionaire-john-paul-digorio-bets-on-aubo-for-cold-sores-and-maybe-more/2458461/Billionaire John Paul DiJoria of Paul Mitchell Professional Hair Care Products and Patron Tequila fame is putting his money where his mouth is --- literally. DeJoria is now investing “heavily” in a new natural and sustainably produced over-the-counter (OTC) col
- UofL Dermatology Chief Tapped by ACCMEhttps://practicaldermatology.com/news/uofl-dermatology-chief-tapped-by-accme/2458477/Jeffrey P. Callen, MD, chief of the Division of Dermatology at the University of Louisville School of Medicine in Kentucky, has been elected to serve on the Accreditation Review Committee (ARC) of the Accreditation Council of Continuing Medical Education (ACCME).
- FDA Cracks Down on Mercury in Anti-Aging Productshttps://practicaldermatology.com/news/fda-cracks-down-on-mercury-in-anti-aging-products/2458488/The U.S. Food and Drug Administration is re-issuing a warning about the dangers of mercury in skin creams, beauty and antiseptic soaps, and lotions. In the past few years, the FDA and state health officials
- Novan: First Patient Dosed in Phase 2 Anti-Fungal Programhttps://practicaldermatology.com/news/nolan-first-patient-dosed-in-phase-2-anti-fungal-program/2458492/The first patient has been dosed in Novan's clinical program to evaluate the efficacy and safety of topical nitric oxide product candidate SB208 in the treatment of infections caused by dermatophytes such as Trichophyton rubrum (“T. rubrum”). Novan is developing
- CeraVe: Suncare Products Get Skin Cancer Foundation Seal of Recommendationhttps://practicaldermatology.com/news/cerave-suncare-products-get-skin-cancer-foundation-seal-of-recommendation/2458495/Two products from Valeant Consumer Healthcare's CeraVe skincare line have received The Skin Cancer Foundation (SCF) Seal of Recommendation for sunscreens. CeraVe® AM Facial Moisturizing Lotion with SPF 30 has earned the “Daily Use” Seal and CeraVe
- Revance's Injectable Toxin to Enter Phase 3 Trialshttps://practicaldermatology.com/news/revances-injectable-toxin-to-enter-phase-3-trials/2458500/It’s game on for Revance Therapeutics, Inc. The company expects to initiate Phase 3 clinical trials of Injectable DaxibotulinumtoxinA (RT002) for the treatment of glabellar lines in the second half of 2016. Revance is moving forward with an